A retrospective study from Yale School of Medicine shows association with overall survival in non-small cell lung cancer (NSCLC) patients treated with PD-1 pathway blockade using a panel of CD8, CD68, PD-L1 in a novel tissue-based multiplex assay

CAMBRIDGE, Mass, November 8, 2018 – Ultivue announced today that the Yale School of Medicine will present data highlighting the utility of a CD8, CD68, PD-L1 quantitative multiplex immunohistochemistry (IHC) panel. In t...

Read More

Ultivue to release a breakthrough 9-Color multiplex IHC panel achieving same day sample-to-analysis at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018

CAMBRIDGE, Mass, November 7, 2018 – Ultivue, a life science company developing reagent-driven strategies for high-performance biological imaging in situ, today announced expanded capabilities of its proprietary InSituPl...

Read More

Unlocking the complexities of cancer biology with BOND RX and Ultivue.

Melbourne, Australia and Cambridge, Massachusetts – October 25, 2018 | Leica Biosystems and Ultivue begin Co-Marketing of UltiMapper™ Assay on the BOND RX enabling single-step automated multiplexing in under 6 hou...

Read More

Ultivue expands its portfolio of Digital Quantitative Pathology Services with a Suite of Image Analysis Capabilities powered by Indica Labs HALO™, HALO LINK™, and Amazon Web Services

CAMBRIDGE, Mass -- September 13, 2018 – Ultivue has announced today the expansion of its menu of Digital Quantitative Pathology Services with a complete suite of Image Analysis capabilities. Building up on the success o...

Read More

From Staining to Analysis: End-to-End Application of UltiMapper™ Kits for Multiplexed Immuno-Profiling

Learn how UltiMapper multiplex IHC assays enable access to whole-slide, highly multiplexed biomarker data optimized on the Leica BOND RX™ autostainer and analyzed using HALO™ image analysis software The tumor i...

Read More

Ultivue launches UltiMapper™ Portfolio of Reagents for Tissue Marker Detection and Analysis at High Level of Multiplexing and Throughput, with Seamless Use in Current Immuno-Histochemistry Workflows

CAMBRIDGE, Mass, July 10, 2018 – Ultivue has announced today the public launch of its UltiMapper™ portfolio of reagents enabling the highest throughput of whole-slide, protein biomarker spatial detection and a...

Read More

Multiplexing in Whole-Slide Tissue Imaging for Life Science

Researchers and clinicians must work across biomarker discovery and companion diagnostic areas to translate the biological complexity of a disease into actionable information. High-content data generation and analysis –...

Read More

Ultivue's Scientific Team Presents Compelling Tissue Marker Multiplexing Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

CAMBRIDGE, Mass, April 16, 2018 – Ultivue has announced today the release of exciting new data illustrating the performance of its proprietary InSituPlex™ technology that powers the company’s reagent offerin...

Read More

Ultivue Inc. Announces Completion of its Series B Financing

CAMBRIDGE, Mass, January 23, 2018--Ultivue, a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, has announced today that it has closed a $20 million Series B funding r...

Read More

Ultivue Inc. Launches InSituPlex™ Services for Whole Slide, High Definition Spatial Multiplex Tissue Biomarker Analysis

CAMBRIDGE, Mass, November 9, 2017--Ultivue has announced today the commercial launch of InSituPlex Services that provide transformative interrogation of protein biomarker expression patterns in tissue. The service offering...

Read More